Recall: D-0774-2022

Class II - Potentially Harmful

Class IIClassification

2022-04-07Initiated

TerminatedStatus

Mylan Pharmaceuticals IncFirm

Product

Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60

Reason

Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

Distribution

Nationwide in the USA

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.